Division of Gastroenterology and HepatologyMayo ClinicRochesterMNUSA.
Department of Medical and Molecular GeneticsIndiana University School of MedicineIndianapolisINUSA.
Hepatol Commun. 2022 Mar;6(3):593-609. doi: 10.1002/hep4.1835. Epub 2021 Oct 22.
Hepatic fibrosis is driven by deposition of matrix proteins following liver injury. Hepatic stellate cells (HSCs) drive fibrogenesis, producing matrix proteins, including procollagen I, which matures into collagen I following secretion. Disrupting intracellular procollagen processing and trafficking causes endoplasmic reticulum stress and stress-induced HSC apoptosis and thus is an attractive antifibrotic strategy. We designed an immunofluorescence-based small interfering RNA (siRNA) screen to identify procollagen I trafficking regulators, hypothesizing that these proteins could serve as antifibrotic targets. A targeted siRNA screen was performed using immunofluorescence to detect changes in intracellular procollagen I. Tumor necrosis factor receptor associated factor 2 and noncatalytic region of tyrosine kinase-interacting kinase (TNIK) was identified and interrogated in vitro and in vivo using the TNIK kinase inhibitor NCB-0846 or RNA interference-mediated knockdown. Our siRNA screen identified nine genes whose knockdown promoted procollagen I retention, including the serine/threonine kinase TNIK. Genetic deletion or pharmacologic inhibition of TNIK through the small molecule inhibitor NCB-0846 disrupted procollagen I trafficking and secretion without impacting procollagen I expression. To investigate the role of TNIK in liver fibrogenesis, we analyzed human and murine livers, finding elevated TNIK expression in human cirrhotic livers and increased TNIK expression and kinase activity in both fibrotic mouse livers and activated primary human HSCs. Finally, we tested whether inhibition of TNIK kinase activity could limit fibrogenesis in vivo. Mice receiving NCB-0846 displayed reduced CCl -induced fibrogenesis compared to CCl alone, although α-smooth muscle actin levels were unaltered. Conclusions: Our siRNA screen effectively identified TNIK as a key kinase involved in procollagen I trafficking in vitro and hepatic fibrogenesis in vivo.
肝纤维化是肝脏损伤后基质蛋白沉积引起的。肝星状细胞(HSCs)驱动纤维化,产生基质蛋白,包括前胶原 I,分泌后成熟为胶原 I。破坏细胞内前胶原加工和运输会导致内质网应激和应激诱导的 HSC 凋亡,因此是一种有吸引力的抗纤维化策略。我们设计了一种基于免疫荧光的小干扰 RNA(siRNA)筛选方法,以鉴定前胶原 I 运输调节剂,假设这些蛋白质可以作为抗纤维化靶点。使用免疫荧光检测细胞内前胶原 I 的变化,进行靶向 siRNA 筛选。使用 TNIK 激酶抑制剂 NCB-0846 或 RNA 干扰介导的敲低,在体外和体内研究肿瘤坏死因子受体相关因子 2 和非催化酪氨酸激酶相互作用激酶(TNIK)。我们的 siRNA 筛选鉴定了九个基因,其敲低可促进前胶原 I 保留,包括丝氨酸/苏氨酸激酶 TNIK。通过小分子抑制剂 NCB-0846 对 TNIK 的遗传缺失或药物抑制会破坏前胶原 I 的运输和分泌,而不影响前胶原 I 的表达。为了研究 TNIK 在肝纤维化中的作用,我们分析了人类和小鼠的肝脏,发现人类肝硬化肝脏中 TNIK 表达升高,纤维化小鼠肝脏和激活的原代人 HSCs 中 TNIK 表达和激酶活性增加。最后,我们测试了抑制 TNIK 激酶活性是否可以限制体内纤维化。与单独 CCl 相比,接受 NCB-0846 治疗的小鼠显示 CCl 诱导的纤维化减少,尽管α-平滑肌肌动蛋白水平未改变。结论:我们的 siRNA 筛选有效地鉴定了 TNIK 作为一种关键激酶,参与了体外前胶原 I 运输和体内肝纤维化。